Coriolis Pharma, a global contract research and development organization, celebrated the opening of its new North America headquarters and laboratory recently, marking the start of operations at the Alexandria Center for Advanced Technologies (ACAT) in North Carolina’s Research Triangle Park (RTP).
The expansion enables Coriolis to provide its North American clients with direct access to specialized expertise in formulation and drug product development as well as analytical characterization of biopharmaceutical products.
“Opening our lab and headquarters in North Carolina is a major leap forward for Coriolis. It fuels our mission to empower innovation where it happens,” said Silvia Steyrer-Gruber, CEO of Coriolis Pharma. “The region’s scientific excellence, cutting-edge biotech and manufacturing ecosystem, and collaborative energy make it the perfect home for our next chapter.”
The new site offers three core services:
- Particle Analysis and Fast Track Analytics – High precision identification and characterization of particles and ad hoc non-GMP analytical services
- Formulation Development – Preclinical, early and late-stage formulation development for liquid, and frozen-liquid products
- Drug Product Development – Primary packaging material selection studies and in-depth drug product and filling process characterization work to support IND/BLA filings.
“Here it's definitely not only about the lab. It's not about the square feet, it's not about the instruments that we have. It's about our commitment,” Steyrer-Gruber said. “We commit to our clients. We have a commitment to our talent. And that's why RTP is so excellent for us, because it really combines all this and how we can be a good partner and how we can grow in scientific excellence.”
Steyrer-Gruber thanked several partners, including the North Carolina Biotechnology Center, for their help in coming to North Carolina. Coriolis has its global headquarters in Martinsreid outside Munich, Germany.
Christian Brown, director of economic development at NCBiotech, welcomed Coriolis and said the state’s biotech ecosystem would also be welcoming.
“You are joining a region that is truly unique, with world-class research universities, responsive community colleges, large global pharma companies, nimble emerging startups,” Brown said. “This is a region where partnerships can form faster, and science moves quicker. We do not doubt that Coriolis will quickly become a personal partner in the community. What you do is critical to getting these new therapists to patients who need them.”
Blake Stevens, executive vice president and regional market director for the Research Triangle at Alexandria Real Estate Equities, Inc., which owns ACAT, said Coriolis’ global business will be right at home in RTP.
“We know that you're working across the world to help patients everywhere,” Stevens said. “We also understand that by selecting Research Triangle Park for your North American headquarters, our ecosystem will be stronger. Thank you for being here. We're thrilled.”